Smad4 is essential for TGF-β-mediated inhibition of ERα estrogenic transcription activity, and the inhibition of Smad4 expression switches TGF-β from a repressor to an activator for ERα transactivation in breast cancer cells. Here, SMAD4 is linked to breast cancer.